TriZetto Data Breach Claims Investigated by Lynch Carpenter

PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- TriZetto Provider Solutions (“TriZetto”),1 recently announced a cybersecurity incident, which impacted the personal information of an unknown number of individuals. Lynch Carpenter, LLP is investigating claims against TriZetto related to this data breach. For an attorney to review your case, visit our site HERE.

In the incident, an unauthorized person gained access to TriZetto’s network and may have acquired records containing personally identifiable information (“PII”) and protected health information (“PHI”) that includes individuals’ names in combination with:

• address
  
• date of birth
• Social Security number
  
• health insurance member number
  
• provider name
  
• health insurer name
  
• primary insured information
  
• other demographic, health, and health insurance information

If your information was impacted in this incident, you may be entitled to compensation. For an attorney to review your case, visit our site HERE.

If you have received any other data breach notice letters in the last 30 days, please contact us here.

About Lynch Carpenter

Lynch Carpenter is a national class action law firm with offices in Pennsylvania, California, and Illinois. Our firm has represented millions of clients in data privacy matters for more than a decade and has earned national acclaim for complex litigation for plaintiffs across the country. To learn more, please visit www.lynchcarpenter.com.

For more information, please call Jerry Wells at (412) 322-9243, or email him at [email protected].

______________________________
1 https://www.trizettoprovider.com/

CONTACT Jerry Wells
COMPANY Lynch Carpenter LLP
PHONE (412) 322-9243
EMAIL [email protected]
WEB lynchcarpenter.com

You May Also Be Interested In

• Orqa U.S. Appoints Major General (Ret.) Rodney D. Lewis, Ph.D., to Board of Directors
• Watch the Kaspi Event: Mikheil Lomtadze Unveils Kasper
• Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases